तुलना करने के लिए मीट्रिक्स | SYNACT | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधSYNACTपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −8.1x | −2.6x | −0.2x | |
PEG अनुपात | −0.53 | −0.05 | 0.00 | |
क़ीमत/बुक | 5.8x | 0.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 146.6x | 2.8x | |
अपसाइड (विश्लेषक लक्ष्य) | 169.1% | 657.1% | 62.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 48.9% | 9.5% | अनलॉक करें |
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.